Prosecution Insights
Last updated: November 04, 2026
Application No. 18/392,449

BIOMATERIALS FROM BIOCARBONATES

Final Rejection §103
Filed
Dec 21, 2023
Priority
Dec 22, 2022 — provisional 63/434,551
Examiner
FORREST, MICHAEL
Art Unit
Tech Center
Assignee
Ginn Ip LLC
OA Round
2 (Final)
60%
Grant Probability
Moderate
3-4
OA Rounds
6m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
465 granted / 778 resolved
At TC average
Moderate +14% lift
Without
With
+13.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
37 currently pending
Career history
829
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
57.7%
+17.7% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
20.6%
-19.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 778 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant's arguments filed 7/27/2026 have been fully considered but they are not persuasive. Applicant argues in the Remarks at Page 10 that Pedroso does not include the use of natural calcium carbonate from snail shells, oyster shells, and seashells. This argument is unpersuasive since claim 1 recites: “ biocarbonates and/or biominerals obtained from a bioresource comprising avian eggshells, snail shells, oyster shells, or seashells…” and Pedroso is cited for teaching a bioresource comprising avian eggshells. Applicant also argues in the Remarks at Page 10 even if the ranges for calcium carbonate content, brightness, and particle size that overlaps with the ranges recited in Claim 1, such overlap does not, by itself, render the claimed subject matter obvious. This argument is not persuasive since as set forth in MPEP 2144.05, in the case where the claimed range “overlap or lie inside ranges disclosed by the prior art”, a prima facie case of obviousness exists, In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed.Cir. 1990). The overlap itself establishes the rebuttable prima facie (presumptive) case of obviousness automatically in contradiction to Applicant’s argument. The burden is on Applicant to rebut the prima facie case of obviousness. See MPEP 2144.05.III. Further regarding Applicant’s argument that the claimed particle characteristic define a specific material having a distinct combination of physical properties that is different from the material described in Pedroso because Pedroso teaches a material comprising the range of calcium carbonate content, brightness, and particle size where he teaches the overlapping ranges. Furthermore, the argument that Pedroso is directed to a different material having different design considerations is in direct contradiction to the claimed product being “usable for products selected from the group consisting of paints, coatings, papers and/or plastics” when Pedroso also teaches particles used as extenders, mineral fillers, and/or pigments in paints. Regarding Applicant’s argument that Gisser ‘398 mentions only functional fillers, the argument is unpersuasive since as a Markush grouping claim 6 encompasses a listing of pigments and fillers alternatives “selected from the group consisting of hydrous fillers, anhydrous fillers and functional fillers”. See MPEP 2117. As admitted in the Remarks by Applicant Pedroso teaches functional fillers. Claim 6 is rejected because the prior art Pedroso and Gisser suggest that a biomaterial of claim 5 combined with a functional filler is an obvious product and is a species within claim 6 rendering claim 6 unpatentable. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1 and 4-5 is/are rejected under 35 U.S.C. 103 as being unpatentable over Pedroso. Regarding claim 1, Pedroso teaches a calcium carbonate-containing material prepared from an avian eggshell (see Page 1, Ln 40 and Page 7, Ln 14). Pedroso further teaches a paint composition comprising the calcium carbonate-containing material (see Page 2, Ln 8-23). Pedroso further teaches a calcium carbonate-containing material containing calcium carbonate in an amount of at least 95 wt% (see Page 4, Ln 24-26). Pedroso further teaches that the calcium carbonate-containing material retains the intrinsic morphology of the avian eggshell and is distinguishable from known geological calcium carbonate by this morphology (i.e., has a morphological difference from natural resource carbonate) (see Page 6, Ln 28-36). Pedroso also teaches a calcium carbonate material with a brightness of 90 to 100% (see Page 10, Ln 15-16). Pedroso teaches a calcium carbonate-containing material wherein the particle size has a d98 of from 1.0 to 25 µm (see Page 27, Ln 18-26). Regarding the biomaterial being sterilized and odor-free, Pedroso teaches the product that is treated with a bleaching agent which also has antimicrobial effect (i.e., where the product is sterilized) (see Page 22, Ln 33 to Page 25, Ln 2 and Page 4, Ln 32-34). Pedroso teaches the product that has no odor (see Page 8, Ln 28-37). Pedroso does not specifically disclose the calcium carbonate in an amount of 95-97% range and brightness from about 88-97 and where the brightness is in the range of 88-97, and particle size of 90% <2 µm. As set forth in MPEP 2144.05, in the case where the claimed range “overlap or lie inside ranges disclosed by the prior art”, a prima facie case of obviousness exists, In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed.Cir. 1990). It would have been obvious to one of ordinary skill in the art at the time of filing of the invention to prepare the calcium carbonate-containing material as taught by Pedroso where the amount of calcium carbonate is in any workable or optimum range overlapping with 95 wt% as taught by Pedroso including the claimed range. It also would have been obvious to one of ordinary skill in the art at the time of filing of the invention to prepare the calcium carbonate-containing material as taught by Pedroso where the brightness is in any workable or optimum range overlapping with 90 to 100 wt% as taught by Pedroso including the claimed range. Regarding particle size 90% < 2 µm , Pedroso teaches a calcium carbonate-containing material wherein the particle size has a d98 of from 1.0 to 25 µm (see Page 27, Ln 18-26). It also would have been obvious to one of ordinary skill in the art at the time of filing of the invention to prepare the calcium carbonate-containing material as taught by Pedroso where the d98 is any workable or optimum range overlapping with 1.0 to 25 µm including 1.0 to less than 2.0 µm for use as an extender, pigment or filler. Furthermore, one of ordinary skill in the art would recognize that the calcium carbonate-containing material having a d98 of less than 2.0 µm also has a d90 of less than 2.0 µm (90% < 2 µm). Regarding claims 4-5, Pedroso teaches the calcium carbonate-containing material that is usable for extenders, mineral fillers and/or pigments in paints (see Page 1, Ln 18-35 and Page 2, Ln 8-23). Claim(s) 6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Pedroso as applied to claim 5 and in further view of Gisser et al (US 2013/0084398). As applied to claim 5, Pedroso teaches a biocarbonate obtained from avian eggshells and a paint composition comprising the biocarbonate. Regarding claim 6, Pedroso teaches an aqueous paint formulation comprising the calcium carbonate-containing material and further comprise pigment and fillers (see Page 29, Ln 25 to Page 30, Ln 20). Pedroso does not teach that the filler is a hydrous filler, anhydrous filler, or functional fillers. Gisser teaches an antimicrobial paint composition where the paint composition comprises combinations of pigments including calcium carbonate as an additional pigment and functional fillers to provide additional functional characteristics to the paint (see [0025]). It would have been obvious to one of ordinary skill in the art at the time of filing of the invention to prepare the paint formulation comprising calcium carbonate-containing material, pigment, and filler as taught by Pedroso where the filler comprises a functional filler as taught by Gisser in order to provide additional functional properties to the paint as suggested by Gisser. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL FORREST whose telephone number is (571)270-5833. The examiner can normally be reached Monday-Friday (10AM-6PM). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sally A Merkling can be reached at (571)272-6297. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL FORREST/Primary Examiner, Art Unit 1738
Read full office action

Prosecution Timeline

Dec 21, 2023
Application Filed
May 14, 2026
Non-Final Rejection mailed — §103
Jul 27, 2026
Response Filed
Oct 06, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779737
METHOD OF PRODUCING RECYCLED REINFORCING FIBERS
3y 4m to grant Granted Nov 03, 2026
Patent 12773376
DENTAL IMPRESSION MATERIAL AND COMBINATION IMPRESSION MATERIAL
4y 4m to grant Granted Oct 27, 2026
Patent 12773687
Hydroformylation Catalyst System with Syngas Surrogate
4y 1m to grant Granted Oct 27, 2026
Patent 12766575
ENHANCED GASIFICATION SYSTEM AND METHOD
3y 8m to grant Granted Oct 20, 2026
Patent 12759277
HYDROPHOBIC SILICA WET GEL AND AEROGEL
2y 5m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
60%
Grant Probability
73%
With Interview (+13.6%)
3y 4m (~6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 778 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month